| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
FDA COMMENTARY |
Division of Oncology Drug Products, Center for Drug Evaluation and Research, United States Food and Drug Administration, Rockville, Maryland, USA
Correspondence: Robert C. Kane, M.D., F.A.C.P., U.S. FDA, HFD-150, 5600 Fishers Lane, Rockville, Maryland 20857, USA. Telephone: 301-594-2473; Fax: 301-594-0499; e-mail kaner{at}cder.fda.gov
Bortezomib (formerly PS-341), a promising new drug for the treatment of multiple myeloma, recently received accelerated approval from the U.S. Food and Drug Administration (FDA) for the therapy of patients with progressive myeloma after previous treatment. Two phase II studies of bortezomib used the same schedule of twice-weekly i.v. dosing for the first 2 weeks of each 3-week cycle. In a randomized study of 54 patients, two doses were compared (1.0 and 1.3 mg/m2) and objective responses occurred at both dose levels (23% versus 35%), including one complete response in each arm. In the other phase II study, 202 heavily pretreated patients (median of six prior therapies) all received the same schedule at 1.3 mg/m2. Of 188 evaluable patients, complete responses occurred in five (3%) and partial responses occurred in 47 (25%). The median duration of response was 365 days. The most clinically relevant adverse events were asthenic conditions, nausea, vomiting, diarrhea, thrombocytopenia, and a peripheral neuropathy that often was painful. This report highlights the FDA analysis supporting the accelerated approval.
This article has been cited by other articles:
 |
|
 |
|
  Y. Jia, T. Song, C. Wei, C. Ni, Z. Zheng, Q. Xu, H. Ma, L. Li, Y. Zhang, X. He, et al. Negative Regulation of MAVS-Mediated Innate Immune Response by PSMA7 J. Immunol., October 1, 2009; 183(7): 4241 - 4248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Zmijewski, S. Banerjee, and E. Abraham S-Glutathionylation of the Rpn2 Regulatory Subunit Inhibits 26 S Proteasomal Function J. Biol. Chem., August 14, 2009; 284(33): 22213 - 22221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Vlashi, K. Kim, C. Lagadec, L. D. Donna, J. T. McDonald, M. Eghbali, J. W. Sayre, E. Stefani, W. McBride, and F. Pajonk In Vivo Imaging, Tracking, and Targeting of Cancer Stem Cells J Natl Cancer Inst, March 4, 2009; 101(5): 350 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hazarika, E. Rock, G. Williams, R. Dagher, R. Sridhara, B. Booth, A. Farrell, R. Justice, and R. Pazdur Lenalidomide in Combination with Dexamethasone for the Treatment of Multiple Myeloma After One Prior Therapy Oncologist, October 1, 2008; 13(10): 1120 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kardosh, E. B. Golden, P. Pyrko, J. Uddin, F. M. Hofman, T. C. Chen, S. G. Louie, N. A. Petasis, and A. H. Schonthal Aggravated Endoplasmic Reticulum Stress as a Basis for Enhanced Glioblastoma Cell Killing by Bortezomib in Combination with Celecoxib or Its Non-Coxib Analogue, 2,5-Dimethyl-Celecoxib Cancer Res., February 1, 2008; 68(3): 843 - 851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Chauhan, A. Singh, M. Brahmandam, K. Podar, T. Hideshima, P. Richardson, N. Munshi, M. A. Palladino, and K. C. Anderson Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma Blood, February 1, 2008; 111(3): 1654 - 1664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Conticello, L. Adamo, R. Giuffrida, L. Vicari, A. Zeuner, A. Eramo, G. Anastasi, L. Memeo, D. Giuffrida, G. Iannolo, et al. Proteasome Inhibitors Synergize with Tumor Necrosis Factor-Related Apoptosis-Induced Ligand to Induce Anaplastic Thyroid Carcinoma Cell Death J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1938 - 1942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Meister, U. Schubert, K. Neubert, K. Herrmann, R. Burger, M. Gramatzki, S. Hahn, S. Schreiber, S. Wilhelm, M. Herrmann, et al. Extensive Immunoglobulin Production Sensitizes Myeloma Cells for Proteasome Inhibition Cancer Res., February 15, 2007; 67(4): 1783 - 1792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Marciniak and D. Ron Endoplasmic reticulum stress signaling in disease. Physiol Rev, October 1, 2006; 86(4): 1133 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-S. Shiah, W. Gao, D. C. Baker, and Y.-C. Cheng Inhibition of cell growth and nuclear factor-{kappa}B activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503. Mol. Cancer Ther., October 1, 2006; 5(10): 2484 - 2493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Canfield, K. Zhu, S. A. Williams, and D. J. McConkey Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Mol. Cancer Ther., August 1, 2006; 5(8): 2043 - 2050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Vij, S. Fang, and P. L. Zeitlin Selective Inhibition of Endoplasmic Reticulum-associated Degradation Rescues {Delta}F508-Cystic Fibrosis Transmembrane Regulator and Suppresses Interleukin-8 Levels: THERAPEUTIC IMPLICATIONS J. Biol. Chem., June 23, 2006; 281(25): 17369 - 17378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Obeng, L. M. Carlson, D. M. Gutman, W. J. Harrington Jr, K. P. Lee, and L. H. Boise Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells Blood, June 15, 2006; 107(12): 4907 - 4916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Khan, J. K. Stauffer, R. Williams, J. A. Hixon, R. Salcedo, E. Lincoln, T. C. Back, D. Powell, S. Lockett, A. C. Arnold, et al. Proteasome Inhibition to Maximize the Apoptotic Potential of Cytokine Therapy for Murine Neuroblastoma Tumors J. Immunol., May 15, 2006; 176(10): 6302 - 6312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Kane, A. T. Farrell, R. Sridhara, and R. Pazdur United States food and drug administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin. Cancer Res., May 15, 2006; 12(10): 2955 - 2960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Berenson, H. H. Yang, K. Sadler, S. G. Jarutirasarn, R. A. Vescio, R. Mapes, M. Purner, S.-p. Lee, J. Wilson, B. Morrison, et al. Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma J. Clin. Oncol., February 20, 2006; 24(6): 937 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Yanamandra, N. M. Colaco, N. A. Parquet, R. W. Buzzeo, D. Boulware, G. Wright, L. E. Perez, W. S. Dalton, and D. M. Beaupre Tipifarnib and Bortezomib Are Synergistic and Overcome Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma and Acute Myeloid Leukemia Clin. Cancer Res., January 15, 2006; 12(2): 591 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Perez-Galan, G. Roue, N. Villamor, E. Montserrat, E. Campo, and D. Colomer The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status Blood, January 1, 2006; 107(1): 257 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Kelloff, K. A. Krohn, S. M. Larson, R. Weissleder, D. A. Mankoff, J. M. Hoffman, J. M. Link, K. Z. Guyton, W. C. Eckelman, H. I. Scher, et al. The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development Clin. Cancer Res., November 15, 2005; 11(22): 7967 - 7985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R Blazar and W. J Murphy Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD) Phil Trans R Soc B, September 29, 2005; 360(1461): 1747 - 1767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-Z. Qin, J. Ziffra, L. Stennett, B. Bodner, B. K. Bonish, V. Chaturvedi, F. Bennett, P. M. Pollock, J. M. Trent, M. J.C. Hendrix, et al. Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma Cells Cancer Res., July 15, 2005; 65(14): 6282 - 6293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. O. Oyajobi, C. M. Shipman, and G. R. Mundy Recent Insights into Myeloma Bone Disease IBMS BoneKEy, May 1, 2005; 2(5): 17 - 25. [Full Text] [PDF]
|
|
|
|
|
|
A. H. Gordon, R. J. O'Keefe, E. M. Schwarz, R. N. Rosier, and J. E. Puzas Nuclear Factor-{kappa}B-Dependent Mechanisms in Breast Cancer Cells Regulate Tumor Burden and Osteolysis in Bone Cancer Res., April 15, 2005; 65(8): 3209 - 3217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dubey and J. H. Schiller Three Emerging New Drugs for NSCLC: Pemetrexed, Bortezomib, and Cetuximab Oncologist, April 1, 2005; 10(4): 282 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Podar and K. C. Anderson The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications Blood, February 15, 2005; 105(4): 1383 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Goy, A. Younes, P. McLaughlin, B. Pro, J. E. Romaguera, F. Hagemeister, L. Fayad, N. H. Dang, F. Samaniego, M. Wang, et al. Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma J. Clin. Oncol., February 1, 2005; 23(4): 667 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Dagher, J. Johnson, G. Williams, P. Keegan, and R. Pazdur Accelerated Approval of Oncology Products: A Decade of Experience J Natl Cancer Inst, October 20, 2004; 96(20): 1500 - 1509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Podar, R. Shringarpure, Y.-T. Tai, M. Simoncini, M. Sattler, K. Ishitsuka, P. G. Richardson, T. Hideshima, D. Chauhan, and K. C. Anderson Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib Cancer Res., October 15, 2004; 64(20): 7500 - 7506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. P. Tansey Death, Destruction, and the Proteasome N. Engl. J. Med., July 22, 2004; 351(4): 393 - 394. [Full Text] [PDF]
|
|
|
|
|
|
K. I. Amiri, L. W. Horton, B. J. LaFleur, J. A. Sosman, and A. Richmond Augmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome Inhibition: Implication for Bortezomib (VELCADE, PS-341) as a Therapeutic Agent for Malignant Melanoma Cancer Res., July 15, 2004; 64(14): 4912 - 4918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. P. Veiby and M. A. Read Chemoresistance: Impact of Nuclear Factor (NF)-{kappa}B Inhibition by Small Interfering RNA: Commentary re J. Guo et al., Enhanced Chemosensitivity to Irinotecan by RNA Interference-Mediated Down-Regulation of the NF-{kappa}B p65 Subunit. Clin Cancer Res 2004;10:3333-3341 Clin. Cancer Res., May 15, 2004; 10(10): 3262 - 3264. [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |
